EUSA Pharma Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From EUSA Pharma Inc.
NICE says that Bavencio plus Inlyta will be made available via the Cancer Drugs Fund for advanced kidney cancer while more evidence is collected to support the combination therapy's routine use on the National Health Service.
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
- Specialty Pharmaceuticals
- Implantable Devices
- Other Names / Subsidiaries
- Cytogen Corporation